Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared a post on LinkedIn:
“One of the most pressing challenges in colorectal cancer care today is ensuring every patient has access to comprehensive biomarker testing at the right time. With multiple new targeted therapies approved just this year, the need to close this gap has never been more urgent. Biomarker testing is a lifeline that can change the trajectory of a patient’s treatment and survival.
That’s why, through Project Cure CRC, we’re launching the Colorectal Cancer Alliance Quality Improvement Study. We’re seeking three healthcare clinics to partner with us to conduct this study. Our goal: accelerate access to comprehensive biomarker testing so every eligible colorectal cancer patient regardless of background or location, receives the care they deserve.
By participating in this initiative, your site will receive:
A co-developed QI project including CRC-specific patient navigation, patient education, and access to molecular testing (if needed)
Clinically relevant educational materials on biomarker testing and guideline-driven treatment options
Financial support to run the QI project at your site
Site-specific data to support your QI goals
We’re especially looking to collaborate with healthcare clinics that: Serve rural and/or underserved urban populations
Treat more than 30 of stage 3–4 colorectal cancer patients each year
Have infrastructure to support biomarker testing (biospecimen handling, navigation, etc.)
Are willing to provide data to help measure and expand impact
Interested in joining or learning more? Contact Cara Schmitt at [email protected].”
More posts featuring Michael Sapienza on OncoDaily.